2008
Evaluation of biological pathways involved in chemotherapy response in breast cancer
Tordai A, Wang J, Andre F, Liedtke C, Yan K, Sotiriou C, Hortobagyi GN, Symmans WF, Pusztai L. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Research 2008, 10: r37. PMID: 18445275, PMCID: PMC2397539, DOI: 10.1186/bcr2088.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Resistance, NeoplasmE2F3 Transcription FactorFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticGenes, p53HumansKi-67 AntigenLymphatic MetastasisMiddle AgedMutationNeoadjuvant TherapyNeoplasm StagingPaclitaxelReceptors, EstrogenSignal TransductionTreatment OutcomeConceptsER-positive breast cancerPathologic complete responseER-positive cancersER-negative cancersGenomic grade indexBreast cancerChemotherapy sensitivityGene signatureER-negative breast cancerProliferation signatureER-positive patientsPositive breast cancerExpression of ERPreoperative paclitaxelProliferation gene signatureCyclophosphamide chemotherapyComplete responseResidual cancerChemotherapy responsePCR groupKi67 expressionEstrogen receptorIntroductionOur goalCancerChemotherapy
2007
HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer
Pusztai L, Andre F, Mazouni C, Liedtke C, Kau S, Frye D, Green M, Gonzalez-Angulo A, Symmans W, Hortobagyi G. HER2 expression and efficacy of preoperative paclitaxel and 5-fluorouracil, cyclophosphamide, doxorubicin chemotherapy in breast cancer. Journal Of Clinical Oncology 2007, 25: 548-548. DOI: 10.1200/jco.2007.25.18_suppl.548.Peer-Reviewed Original ResearchPathologic complete responseHER2 overexpressionPCR rateBreast cancerER- cancersHER2- diseaseHER2 expressionRelapse-free survival rateER-negative statusWeekly paclitaxel regimenMicrotubule associated protein tauHigh nuclear gradePaclitaxel regimenPreoperative paclitaxelFAC chemotherapyPreoperative chemotherapyComplete responseHER2 tumorsHER2 statusDoxorubicin chemotherapyNuclear gradeRetrospective analysisPatientsTaxane sensitivitySurvival rateMicrotubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer
Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, Wang B, Hortobagyi GN, Symmans WF, Pusztai L. Microtubule-Associated Protein-tau is a Bifunctional Predictor of Endocrine Sensitivity and Chemotherapy Resistance in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research 2007, 13: 2061-2067. PMID: 17404087, DOI: 10.1158/1078-0432.ccr-06-2078.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDrug Resistance, NeoplasmEstrogen Receptor ModulatorsFemaleGene ExpressionGene Expression ProfilingHumansMiddle AgedNeoplasms, Hormone-DependentPrognosisReceptors, EstrogenRNA, MessengerTamoxifenTau ProteinsConceptsTau mRNA expressionBreast cancerPredictive valueTau expressionMRNA expressionEndocrine therapyEstrogen receptor-positive breast cancerPositive primary breast cancerReceptor-positive breast cancerER-positive breast cancerBorderline nonsignificant associationLow tau expressionPure prognostic valueSystemic adjuvant therapyTaxane-containing chemotherapyChemotherapy-resistant diseasePathologic complete responseER-positive cancersPrimary breast cancerDifferent outcome groupsWilcoxon rank sum testRank sum testAdjuvant tamoxifenPreoperative paclitaxelAdjuvant therapy
2005
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy. Clinical Cancer Research 2005, 11: 5678-5685. PMID: 16115903, DOI: 10.1158/1078-0432.ccr-04-2421.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBiopsy, NeedleBreastBreast NeoplasmsCluster AnalysisDoxorubicinFemaleFluorouracilGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedMultivariate AnalysisOligonucleotide Array Sequence AnalysisPaclitaxelPredictive Value of TestsPreoperative CareReceptor, ErbB-2ConceptsPathologic complete responseComplete responsePreoperative chemotherapyBreast cancerEstrogen receptor-negative subtypesPathologic CR rateEstrogen receptor statusBasal-like groupDifferent molecular subtypesFine-needle aspirationAffymetrix U133A microarraysPreoperative paclitaxelCyclophosphamide chemotherapyReceptor statusCR rateLuminal tumorsDifferent prognosisNuclear gradeMolecular subtypesNeedle aspirationChemotherapy sensitivityChemotherapyCancerMolecular classificationHuman tumors